

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

SU.86.86

RRID:CVCL_3881

Type: Cell Line

Proper Citation

RRID:CVCL_3881

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3881

Proper Citation: RRID:CVCL_3881

Description: Cell line SU.86.86 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:3264833](#), [PMID:10027410](#), [PMID:11115575](#), [PMID:15126341](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU.86.86

Synonyms: Su.86.86, SU 86.86, SU-86-86, Su-86-86, SU86.86, SU86-86, SU86_86, Su86_86, SU8686, SU.86

Cross References: BTO:BTO_0001904, CLO:CLO_0009150, EFO:EFO_0006494, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1837, BioGRID_ORCS_Cell_line:196, BioSample:SAMN03472014,

BioSample:SAMN10987701, cancercellines:CVCL_3881, Cell_Model_Passport:SIDM01188, CGH-DB:183-1, CGH-DB:9282-4, ChEMBL-Cells:ChEMBL4630607, ChEMBL-Targets:ChEMBL4630707, Cosmic:707252, Cosmic:868244, Cosmic:873003, Cosmic:913314, Cosmic:922250, Cosmic:923172, Cosmic:932522, Cosmic:949237, Cosmic:1006362, Cosmic:1066203, Cosmic:1122349, Cosmic:1218879, Cosmic:1358486, Cosmic:1518237, Cosmic:1644315, Cosmic:1995645, Cosmic:2434090, Cosmic-CLP:1240218, DepMap:ACH-000114, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240218, GEO:GSM206545, GEO:GSM621901, GEO:GSM784693, GEO:GSM887650, GEO:GSM888742, GEO:GSM1024414, GEO:GSM1374903, GEO:GSM1435693, GEO:GSM1435694, GEO:GSM1435695, GEO:GSM1670481, IARC_TP53:2860, IZSLER:BS TCL 180, LiGeA:CCLE_401, LINCS_LDP:LCL-1747, PharmacDB:SU_86_86_1506_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_3881, PubChem_Cell_line:CVCL_3881, SKY/M-FISH/CGH:2000, Wikidata:Q54970749

ID: CVCL_3881

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260815T235919+0000

Ratings and Alerts

No rating or validation information has been found for SU.86.86.

No alerts have been found for SU.86.86.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chang WH, et al. (2026) Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. bioRxiv : the preprint server for biology.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Garczyk M, et al. (2026) Targeting PI3K?? suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Cell reports, 45(4), 117188.

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 596.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(13), 3194.

Stukas D, et al. (2025) Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. *Biochemical pharmacology*, 233, 116798.

Jakubecova J, et al. (2025) Combined action of suicide gene exosomes from pancreatic cancer-associated fibroblasts and from mesenchymal stem cells as a pancreatic ductal adenocarcinoma treatment approach. *Cancer cell international*, 26(1), 35.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.

Ren L, et al. (2025) Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. *Cancer cell*.

Khine HEE, et al. (2025) Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways. *Scientific reports*, 15(1), 11376.

Drizyte-Miller K, et al. (2025) Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. *Cancer research*, 85(18), 3540.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. *Nature communications*, 16(1), 4866.

Ohara Y, et al. (2024) ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. *International journal of cancer*, 155(3), 569.

Sonnemann HM, et al. (2024) Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. *Frontiers in oncology*, 14, 1403052.

Moreno P, et al. (2024) ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. *Carcinogenesis*, 45(11), 845.

Tao J, et al. (2024) CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. *Journal of experimental & clinical cancer research : CR*, 43(1), 277.

Zhang S, et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. *Cell death discovery*, 10(1), 124.

Han X, et al. (2024) Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. *Cell reports*, 43(11), 114972.

Ohara Y, et al. (2024) LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. *Carcinogenesis*.